By Laura Lutz
Des Moines, April 18 - Ambrilia Biopharma Inc. intends to conduct a private placement of shares for C$5.4 million.
The company plans to sell 2,231,405 shares at C$2.42 each, the volume weighted average price of the company's common shares for the five days ended April 11.
The investors include Turenne Capital Partenaires, Innoven Partenaires, OTC Asset Management and DHR Investissement.
Settlement is expected on May 18.
Ambrilia is a Montreal-based biopharmaceutical company.
| Issuer: | Ambrilia Biopharma Inc.
|
| Issue: | Shares
|
| Amount: | C$5.4 million
|
| Shares: | 2,231,405
|
| Price: | C$2.42
|
| Warrants: | No
|
| Investors: | Turenne Capital Partenaires, Innoven Partenaires, OTC Asset Management, DHR Investissement
|
| Pricing date: | April 18
|
| Settlement date: | May 18
|
| Stock symbol: | Toronto: AMB
|
| Stock price: | C$2.65 at close April 18
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
